Jiangsu Yongda Pharmaceutical Co., Ltd. is located in Changzhou Binjiang Chemical Zone of beautiful and rich south bank of Yangtze River. It produces over 50 varieties of medical bulk materials and medical intermediates.

Based on domestic famous research institutes and universities, we have formed intensive and large-scale production according to GMP requirements. We have top grade equipments, excellent testing instrument and professional staffs. Currently, our company has become domestic large production base of gatifloxacin. Meanwhile, we have technological superiority and superior production scale in manufacturing of perindopril tert-butylamine salt intermediate, Indoline-2-carboxylic acid series products. Four bulk pharmaceutical materials have passed state GMP authentication. Another two are under application and examination. In addition, we have a great advantage in high-pressure hydrogenation reaction and enzymic catalytic reaction.

40% of our employees are with college degree, bachelor degree or above. In 2003, scientific and technology research institute was established. Since establishment, we continuously develop and research new products, insisting on principle of steady and fast development.

Company history
In 1992, Jiangyin Yongda Chemical Co., Ltd., our predecessor, was established in Huangtu Town of Jiangyin City. Its representative product is monochloroacetone.
In 2003, Jiangsu Yongda Pharmaceutical Co., Ltd. was established. It began to produce gatifloxacin. In later 10 years, it got GMP certificate of multiple bulk pharmaceutical materials, such as, gatifloxacin and Balofloxacin.
In 2005, Changzhou Da’ou Chemical Co., Ltd. was established in Changzhou Binjiang High-tech Development Zone. It takes high-pressure hydrogenation as its characteristic project. And we constantly optimize product structure.
In 2014, in order to realize remarkable progress and development, original Jiangsu Yongda Pharmaceutical Co., Ltd. and Changzhou Da’ou Chemical Co., Ltd. were merged, and present Jiangsu Yongda Pharmaceutical Co., Ltd. was formed.